{
"id":"mk19_bb_hm_s1",
"subspecialtyId":"hm",
"title":"Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria",
"jsonContent":{
"type":"section",
"id":"mk19_bb_hm_s1",
"title":{
"__html":"Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria"
},
"titleNode":{
"type":"section-title",
"hlId":"4d7414",
"children":[
"Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_hm_s1_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"4811d6",
"children":[
"Aplastic anemia is a disorder in which hematopoietic stem cells are severely diminished, resulting in hypocellular bone marrow and pancytopenia. All cell lines are involved. Autoimmune attack on stem cells is the most common identifiable cause. Other causes include toxins, ionizing radiation, drugs, nutritional deficiencies, and infections."
]
},
{
"type":"p",
"hlId":"5097d9",
"children":[
{
"type":"abbreviation",
"title":"paroxysmal nocturnal hemoglobinuria",
"children":[
"PNH"
]
},
" results from a genetic mutation of membrane proteins that ameliorate complement-mediated destruction of erythrocytes. PNH can be isolated or associated with ",
{
"type":"abbreviation",
"title":"myelodysplastic syndromes",
"children":[
"MDS"
]
},
" and aplastic anemia. PNH is characterized by:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"179a3e",
"children":[
"chronic intravascular hemolytic anemia"
]
},
" ",
{
"type":"list-item",
"hlId":"0f37bf",
"children":[
"iron deficiency through urinary losses"
]
},
" ",
{
"type":"list-item",
"hlId":"7bf86b",
"children":[
"arterial and venous thrombosis ",
{
"type":"alert",
"children":[
"(including Budd-Chiari syndrome)"
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"712324",
"children":[
"pancytopenia"
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s1_2",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"efe0a9",
"children":[
"The basic evaluation of patients presenting with pancytopenia includes:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"6c60ac",
"children":[
"bone marrow aspirate and biopsy (hypocellular with increased fat content)"
]
},
" ",
{
"type":"list-item",
"hlId":"e0f6b3",
"children":[
"cytogenetic analysis to exclude other bone marrow disorders (e.g., MDS)"
]
},
" ",
{
"type":"list-item",
"hlId":"f435e2",
"children":[
"PNH screening flow cytometry with absent CD55 and CD59 cell surface markers"
]
},
" ",
{
"type":"list-item",
"hlId":"27282c",
"children":[
"vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" and folate levels, hepatitis serologies, and HIV testing"
]
},
" "
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_hm_f01"
],
"forceOpen":true
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s1_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"711153",
"children":[
"Initial treatment of ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"aplastic anemia"
]
},
" involves withdrawal of any potentially causative agents. Allogeneic ",
{
"type":"abbreviation",
"title":"hematopoietic stem cell transplantation",
"children":[
"HSCT"
]
},
" is a potentially curative therapy and should be considered for those younger than 50 years who have a suitable match. Immunosuppression with cyclosporine and antithymocyte globulin is also effective first-line therapy and leads to disease control in 70% of adult patients."
]
},
{
"type":"p",
"hlId":"033009",
"children":[
"In symptomatic patients with ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"PNH"
]
},
", eculizumab or ravulizumab reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion. Patients should receive meningococcal vaccination before use because of an increased risk of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria"
]
},
" infections. Allogeneic HSCT can lead to long-term survival. Prophylactic anticoagulation and supplementation with iron and folic acid are indicated in all patients."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"861993",
"children":[
"Treatment of aplastic anemia with hematopoietic growth factors is ineffective."
]
},
" ",
{
"type":"list-item",
"hlId":"25076e",
"children":[
"PNH may present as a ",
{
"type":"abbreviation",
"title":"direct antiglobulin test",
"children":[
"DAT"
]
},
"-negative hemolytic anemia or as aplastic anemia."
]
},
" "
]
}
]
}
]
},
"tablesContent":{
}
}